AT408549B - Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes - Google Patents

Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes Download PDF

Info

Publication number: AT408549B
Authority: AT; Austria
Prior art keywords: virus; recombinant; antigen; gene; promoter
Prior art date: 1987-08-28

Application number

AT0900788A

Other languages

German (de)

English (en)

Other versions

ATA900788A (de

Original Assignee

Health Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-28

Filing date

1988-08-24

Publication date

2001-12-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT408549(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-08-24 Application filed by Health Research Inc filed Critical Health Research Inc

1995-05-15 Publication of ATA900788A publication Critical patent/ATA900788A/de

2001-12-27 Application granted granted Critical

2001-12-27 Publication of AT408549B publication Critical patent/AT408549B/de

Links

241000700605 Viruses Species 0.000 title claims description 185
108090000623 proteins and genes Proteins 0.000 title claims description 130
238000000034 method Methods 0.000 title claims description 42
108010008038 Synthetic Vaccines Proteins 0.000 title description 2
206010037742 Rabies Diseases 0.000 claims description 84
238000002255 vaccination Methods 0.000 claims description 77
239000000427 antigen Substances 0.000 claims description 64
108091007433 antigens Proteins 0.000 claims description 64
102000036639 antigens Human genes 0.000 claims description 64
206010046865 Vaccinia virus infection Diseases 0.000 claims description 47
208000007089 vaccinia Diseases 0.000 claims description 47
241000700663 Avipoxvirus Species 0.000 claims description 44
238000012360 testing method Methods 0.000 claims description 43
230000014509 gene expression Effects 0.000 claims description 40
229960005486 vaccine Drugs 0.000 claims description 39
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 38
230000028993 immune response Effects 0.000 claims description 33
241000283973 Oryctolagus cuniculus Species 0.000 claims description 31
241000714165 Feline leukemia virus Species 0.000 claims description 29
241001465754 Metazoa Species 0.000 claims description 27
244000052769 pathogen Species 0.000 claims description 23
210000002966 serum Anatomy 0.000 claims description 23
108091026890 Coding region Proteins 0.000 claims description 22
241000283690 Bos taurus Species 0.000 claims description 18
241000124008 Mammalia Species 0.000 claims description 18
238000000338 in vitro Methods 0.000 claims description 17
230000001717 pathogenic effect Effects 0.000 claims description 17
241000714266 Bovine leukemia virus Species 0.000 claims description 16
241000700662 Fowlpox virus Species 0.000 claims description 16
108091029865 Exogenous DNA Proteins 0.000 claims description 14
241000699670 Mus sp. Species 0.000 claims description 14
238000010790 dilution Methods 0.000 claims description 12
239000012895 dilution Substances 0.000 claims description 12
241000700584 Simplexvirus Species 0.000 claims description 11
230000010076 replication Effects 0.000 claims description 10
230000003612 virological effect Effects 0.000 claims description 10
241000178270 Canarypox virus Species 0.000 claims description 8
241000282326 Felis catus Species 0.000 claims description 8
241001494479 Pecora Species 0.000 claims description 7
241000894007 species Species 0.000 claims description 7
241000282472 Canis lupus familiaris Species 0.000 claims description 5
238000004113 cell culture Methods 0.000 claims description 5
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
230000009467 reduction Effects 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 3
102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 2
230000001737 promoting effect Effects 0.000 claims 2
241000282887 Suidae Species 0.000 claims 1
238000012606 in vitro cell culture Methods 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
239000013612 plasmid Substances 0.000 description 134
239000012634 fragment Substances 0.000 description 103
210000004027 cell Anatomy 0.000 description 64
208000015181 infectious disease Diseases 0.000 description 55
239000013598 vector Substances 0.000 description 44
241000287828 Gallus gallus Species 0.000 description 42
235000013330 chicken meat Nutrition 0.000 description 42
238000003780 insertion Methods 0.000 description 41
230000037431 insertion Effects 0.000 description 41
241000271566 Aves Species 0.000 description 40
238000010276 construction Methods 0.000 description 40
108020004414 DNA Proteins 0.000 description 38
102000053602 DNA Human genes 0.000 description 38
244000144977 poultry Species 0.000 description 36
235000013594 poultry meat Nutrition 0.000 description 35
108010005774 beta-Galactosidase Proteins 0.000 description 34
230000006798 recombination Effects 0.000 description 34
108091034117 Oligonucleotide Proteins 0.000 description 32
241000700618 Vaccinia virus Species 0.000 description 32
208000000666 Fowlpox Diseases 0.000 description 30
238000005215 recombination Methods 0.000 description 29
201000006082 Chickenpox Diseases 0.000 description 26
206010046980 Varicella Diseases 0.000 description 26
101710154606 Hemagglutinin Proteins 0.000 description 22
101710093908 Outer capsid protein VP4 Proteins 0.000 description 22
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 22
101710176177 Protein A56 Proteins 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108090000288 Glycoproteins Proteins 0.000 description 21
102000005936 beta-Galactosidase Human genes 0.000 description 21
102000003886 Glycoproteins Human genes 0.000 description 20
239000000185 hemagglutinin Substances 0.000 description 19
108010061100 Nucleoproteins Proteins 0.000 description 18
108700004025 env Genes Proteins 0.000 description 18
101150030339 env gene Proteins 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
102000011931 Nucleoproteins Human genes 0.000 description 16
239000011159 matrix material Substances 0.000 description 16
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 15
101150082239 G gene Proteins 0.000 description 15
241000711450 Infectious bronchitis virus Species 0.000 description 15
239000002773 nucleotide Substances 0.000 description 15
125000003729 nucleotide group Chemical group 0.000 description 15
102000004594 DNA Polymerase I Human genes 0.000 description 14
108010017826 DNA Polymerase I Proteins 0.000 description 14
230000003902 lesion Effects 0.000 description 14
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
230000036961 partial effect Effects 0.000 description 13
238000002965 ELISA Methods 0.000 description 12
241000700647 Variola virus Species 0.000 description 12
230000029087 digestion Effects 0.000 description 12
230000004044 response Effects 0.000 description 12
238000013519 translation Methods 0.000 description 12
241001135961 Amsacta moorei entomopoxvirus Species 0.000 description 11
241000711404 Avian avulavirus 1 Species 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
238000003018 immunoassay Methods 0.000 description 10
238000001114 immunoprecipitation Methods 0.000 description 10
206010022000 influenza Diseases 0.000 description 10
238000011081 inoculation Methods 0.000 description 10
108700026244 Open Reading Frames Proteins 0.000 description 9
230000000890 antigenic effect Effects 0.000 description 9
239000006166 lysate Substances 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
229920002477 rna polymer Polymers 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
108091081024 Start codon Proteins 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
230000002458 infectious effect Effects 0.000 description 8
230000007017 scission Effects 0.000 description 8
241000712461 unidentified influenza virus Species 0.000 description 8
238000010367 cloning Methods 0.000 description 7
210000002257 embryonic structure Anatomy 0.000 description 7
230000036039 immunity Effects 0.000 description 7
238000007918 intramuscular administration Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000002356 single layer Substances 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
241000711798 Rabies lyssavirus Species 0.000 description 6
241000287219 Serinus canaria Species 0.000 description 6
230000034994 death Effects 0.000 description 6
231100000517 death Toxicity 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
238000010186 staining Methods 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
235000013601 eggs Nutrition 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
239000000523 sample Substances 0.000 description 5
241000238631 Hexapoda Species 0.000 description 4
206010062016 Immunosuppression Diseases 0.000 description 4
241000286209 Phasianidae Species 0.000 description 4
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
238000004140 cleaning Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000003362 replicative effect Effects 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
230000000405 serological effect Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
101150110188 30 gene Proteins 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
230000004543 DNA replication Effects 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
101150039660 HA gene Proteins 0.000 description 3
241000700721 Hepatitis B virus Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000007710 freezing Methods 0.000 description 3
101150036031 gD gene Proteins 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000012447 hatching Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
210000002729 polyribosome Anatomy 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000010257 thawing Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000001890 transfection Methods 0.000 description 3
241000700570 unidentified entomopoxvirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
101100333573 Bovine leukemia virus env gene Proteins 0.000 description 2
101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
102100030796 E3 ubiquitin-protein ligase rififylin Human genes 0.000 description 2
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
101100484387 Fowlpox virus FPV127 gene Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000703348 Homo sapiens E3 ubiquitin-protein ligase rififylin Proteins 0.000 description 2
241000255777 Lepidoptera Species 0.000 description 2
101150118742 NP gene Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
241000713824 Rous-associated virus Species 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
235000021186 dishes Nutrition 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000004927 fusion Effects 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
229960000380 propiolactone Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000004448 titration Methods 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
101150017816 40 gene Proteins 0.000 description 1
108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
241000670670 Amsacta Species 0.000 description 1
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
101100287651 Caenorhabditis elegans kbp-3 gene Proteins 0.000 description 1
241000173351 Camvirus Species 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
241000254173 Coleoptera Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
241000700572 Entomopoxvirinae Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010069540 Generalised vaccinia Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
208000002979 Influenza in Birds Diseases 0.000 description 1
229940124873 Influenza virus vaccine Drugs 0.000 description 1
HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
241001415864 Lagopus Species 0.000 description 1
241000721703 Lymantria dispar Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
JLNMSNDDYBZCIB-UHFFFAOYSA-N OOOOS Chemical compound OOOOS JLNMSNDDYBZCIB-UHFFFAOYSA-N 0.000 description 1
241000238814 Orthoptera Species 0.000 description 1
241000287127 Passeridae Species 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
208000027954 Poultry disease Diseases 0.000 description 1
229940124939 Pox vaccine Drugs 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
241000714233 Rous-associated virus type 1 Species 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
241000287231 Serinus Species 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
108010059722 Viral Fusion Proteins Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
206010064097 avian influenza Diseases 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
210000003555 cloaca Anatomy 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000012757 fluorescence staining Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
108010077284 hepatitis B surface antigen presurface protein 2 Proteins 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004237 neck muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000018040 scab formation Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000000966 temporal muscle Anatomy 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000006490 viral transcription Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
101150069452 z gene Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT0900788A 1987-08-28 1988-08-24 Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes AT408549B (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US9071187A	1987-08-28	1987-08-28
US11033587A	1987-10-20	1987-10-20
US18605488A	1988-04-25	1988-04-25
US23439088A	1988-08-23	1988-08-23
PCT/US1988/002816 WO1989003429A1 (en)	1987-08-28	1988-08-24	Recombinant avipox virus

Publications (2)

Publication Number	Publication Date
ATA900788A ATA900788A (de)	1995-05-15
AT408549B true AT408549B (de)	2001-12-27

Family

ID=27492413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT0900788A AT408549B (de)	1987-08-28	1988-08-24	Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes

Country Status (17)

Country	Link
JP (3)	JP3348156B2 (da)
KR (1)	KR970011149B1 (da)
AR (1)	AR241939A1 (da)
AT (1)	AT408549B (da)
AU (2)	AU2427588A (da)
BE (1)	BE1002134A5 (da)
CH (2)	CH679934A5 (da)
DE (4)	DE10399031I1 (da)
DK (1)	DK175904B1 (da)
FR (1)	FR2621487B1 (da)
GB (1)	GB2217718B (da)
IL (1)	IL87581A0 (da)
IT (1)	IT1229484B (da)
LU (2)	LU90951I2 (da)
NL (4)	NL195051C (da)
NZ (1)	NZ225970A (da)
WO (1)	WO1989003429A1 (da)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) *	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US7045313B1 (en)	1982-11-30	2006-05-16	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
US5286639A (en) *	1987-09-16	1994-02-15	Nippon Zeon Co., Ltd.	Recombinant avipoxvirus
DE3813093A1 (de) *	1988-04-19	1989-11-09	Immuno Ag	Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
DE68912441T2 (de) *	1988-06-24	1994-05-11	British Tech Group	Nichtessentielle Geflügelpockenvirus-Regionen.
US5093258A (en) *	1988-08-26	1992-03-03	Therion Biologics Corporation	Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) *	1988-10-21	1990-04-21	Matthew M. Binns	Fowlpox virus promoter
US6248333B1 (en)	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) *	1990-02-14	1993-04-20	Health Research Incorporated	Recombinant poxvirus internal cores
MY109299A (en) *	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) *	1990-08-15	1996-05-07	Virogenetics Corporation	Flavivirus recombinant poxvirus vaccine
FR2668064B1 (fr)	1990-10-23	1994-12-16	Transgene Sa	Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) *	1990-11-20	1998-05-26	Virogenetics Corporation	Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5503834A (en) *	1990-11-20	1996-04-02	Virogenetics Corporation	Measles virus recombinant poxvirus vaccine
IE71643B1 (en) *	1990-11-20	1997-02-26	Virogenetics Corp	A recombinant poxviral vaccine for canine distemper
US5759841A (en) *	1990-11-20	1998-06-02	Virogenetics Corporation	Immunological composition of measles virus utilizing recombinant poxvirus
US6309647B1 (en)	1999-07-15	2001-10-30	Aventis Pasteur	Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5338679A (en) *	1991-01-08	1994-08-16	Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada	Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5766597A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Malaria recombinant poxviruses
US5756101A (en) *	1991-07-01	1998-05-26	Pasteur Merieux Serums Et Vaccins	Malaria recombinant poxvirus
US5863542A (en) *	1991-03-07	1999-01-26	Virogenetics Corporation	Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
EP0575491B1 (en) *	1991-03-07	2003-08-13	Virogenetics Corporation	Genetically engineered vaccine strain
US5766598A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
CA2106464A1 (en) *	1991-03-20	1992-09-21	Enzo Paoletti	Malaria recombinant poxvirus vaccine
EP1156102A1 (en) *	1991-06-14	2001-11-21	Virogenetics Corporation	Immunodeficiency virus recombinant poxvirus vaccine
JPH06509235A (ja) *	1991-07-26	1994-10-20	ヴァイロジェネティクス　コーポレイション	伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
ES2212795T3 (es) *	1991-08-26	2004-08-01	Baxter Healthcare S.A.	Virus de la viruela de las aves de corral recombinante.
US5443831A (en) *	1991-10-29	1995-08-22	University Of Delaware	Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6127163A (en) *	1992-01-13	2000-10-03	Syntro Corporation	Recombinant swinepox virus
US6328975B1 (en)	1992-01-13	2001-12-11	Syntro Corporation	Recombinant swinepox virus
US6033904A (en) *	1992-01-13	2000-03-07	Syntro Corporation	Recombinant swinepox virus
US6497882B1 (en)	1992-01-13	2002-12-24	Syntro Corporation	Recombinant swinepox virus
AU680609B2 (en) *	1992-01-13	1997-08-07	Virogenetics Corporation	Marek's disease virus recombinant poxvirus vaccine
US6251403B1 (en)	1992-01-13	2001-06-26	Syntro Corporation	Recombinant swinepox virus
US5869312A (en) *	1992-01-13	1999-02-09	Syntro Corporation	Recombinant swinepox virus
AU5138293A (en) *	1992-09-21	1994-04-12	Chiron Viagene, Inc.	Recombinant retroviral vector against felv and/or fiv
CA2156423A1 (en) *	1993-02-26	1994-09-01	Mark D. Cochran	Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) *	1993-02-26	2000-12-07	Syntro Corporation	Recombinant fowlpox viruses and uses thereof II
US5925358A (en) *	1993-02-26	1999-07-20	Syntro Corporation	Recombinant fowlpox viruses and uses thereof
US6136318A (en) *	1993-02-26	2000-10-24	Cochran; Mark D.	Recombinant fowlpox viruses and uses thereof
US5496731A (en) *	1993-03-25	1996-03-05	Xu; Hong-Ji	Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en)	1995-07-10	1997-01-15	Immuno Ag	Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) *	1995-12-01	1999-01-12	Virogenetics Corporation	Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
EP0954593A1 (en)	1996-07-25	1999-11-10	Therion Biologics Corporation	Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) *	1997-05-07	2000-08-22	University Of Florida	Entomopoxvirus-vertebrate gene delivery vector and method
AU3910097A (en) *	1997-08-05	1999-03-01	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6248582B1 (en) *	1997-10-08	2001-06-19	Imran Khan	Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja)	1997-12-01	1999-06-22	Lintec Corp	チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
EP1141313A2 (en)	1998-12-31	2001-10-10	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU5773500A (en)	1999-06-28	2001-01-31	Board Of Trustees Of The University Of Illinois, The	Inhibitors of memapsin 2 and use thereof
WO2001062778A2 (en)	2000-02-23	2001-08-30	Smithkline Beecham Biologicals S.A.	Tumour-specific animal proteins
EP1319069B1 (en)	2000-06-28	2008-05-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
ATE499948T1 (de)	2001-01-12	2011-03-15	Novartis Vaccines & Diagnostic	Nukleinsäure mukosale immunisierung
CN1258596C (zh) *	2001-03-08	2006-06-07	阿克佐诺贝尔公司	基于野兔痘的载体疫苗
JP4499311B2 (ja) *	2001-04-27	2010-07-07	シャープ株式会社	放送受信端末
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
JP4302513B2 (ja)	2001-07-05	2009-07-29	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
US7211659B2 (en)	2001-07-05	2007-05-01	Chiron Corporation	Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
DK1581119T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
KR101110889B1 (ko)	2003-01-06	2012-02-20	코릭사 코포레이션	특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및그들의 용도
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2525825A1 (en)	2003-05-15	2005-01-27	Chiron Corporation	Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
AU2005287505A1 (en)	2004-09-22	2006-03-30	Biosynexus Incorporated	Staphylococcal immunogenic compositions
EP2360175B1 (en)	2005-11-22	2014-07-16	Novartis Vaccines and Diagnostics, Inc.	Norovirus and Sapovirus virus-like particles (VLPs)
WO2007120368A2 (en)	2006-01-09	2007-10-25	The Regents Of The University Of California	Immunostimulatory combinations for vaccine adjuvants
EP2441470B1 (en)	2006-03-14	2014-05-07	Oregon Health and Science University	Methods for producing an immune response to tuberculosis
CA2678404C (en)	2007-02-28	2019-03-19	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
AU2008314485B9 (en)	2007-10-15	2015-02-26	Jingang Medicine (Australia) Pty Ltd	Expression system for modulating an immune response
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
BRPI1005670A8 (pt)	2009-01-05	2017-12-26	Epitogenesis Inc	composições adjuvantes e processos de uso.
WO2010099472A2 (en)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Spanx-b polypeptides and their use
CN102713629B (zh)	2009-11-20	2016-02-24	俄勒冈健康科学大学	用于检测结核分枝杆菌感染的方法
US20130052221A1 (en)	2010-02-26	2013-02-28	The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services	Dna-protein vaccination protocols
US9795658B2 (en)	2010-04-20	2017-10-24	Admedus Vaccines Pty Ltd	Expression system for modulating an immune response
US9428565B2 (en)	2011-01-31	2016-08-30	The General Hospital Corporation	Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012151272A2 (en)	2011-05-02	2012-11-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
MX2013013627A (es)	2011-06-21	2014-04-25	Oncofactor Corp	Composiciones y metodos para la terapia y diagnostico de cancer.
JP6499446B2 (ja)	2011-06-24	2019-04-10	エピットジェネシス・インコーポレーテッド	抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
US20150004144A1 (en)	2011-12-02	2015-01-01	The General Hospital Corporation	Differentiation into brown adipocytes
EP2890720B1 (en)	2012-08-30	2019-07-17	The General Hospital Corporation	Compositions and methods for treating cancer
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
US20150224181A1 (en)	2012-09-14	2015-08-13	The United States Of America As Represented By The Secretary Department Of Health And Human Se	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CA2909706C (en)	2013-04-17	2023-02-14	Genzyme Corporation	Use of an il17 inhibitor for treating and preventing macular degeneration
US9988617B2 (en)	2013-05-21	2018-06-05	President And Fellows Of Harvard College	Engineered heme-binding compositions and uses thereof
US10172916B2 (en)	2013-11-15	2019-01-08	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201606101WA (en)	2014-02-06	2016-08-30	Genzyme Corp	Compositions and methods for treating and preventing macular degeneration
EP3194446B1 (en)	2014-09-18	2022-10-26	Cedars-Sinai Medical Center	Compositions and methods for treating fibrosis
WO2016154010A1 (en)	2015-03-20	2016-09-29	Makidon Paul	Immunogenic compositions for use in vaccination against bordetella
EP3283529B1 (en)	2015-04-17	2023-06-07	The General Hospital Corporation	Agents, systems and methods for treating cancer
WO2016172479A1 (en)	2015-04-22	2016-10-27	Cedars-Sinai Medical Center	Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
ES2959642T3 (es)	2015-05-13	2024-02-27	The Us Secretary Of The Department Of Health And Human Services	Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en)	2015-05-29	2016-12-08	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en)	2015-06-29	2020-12-23	The Board of Trustees of the Leland Stanford Junior University	Degron fusion constructs and methods for controlling protein production
EP3386593A4 (en)	2015-12-09	2019-07-24	Admedus Vaccines Pty Ltd	IMMUNOMODULATING COMPOSITION FOR TREATMENT
NZ749593A (en)	2016-06-20	2025-10-31	Univ Leland Stanford Junior	Circular rnas and their use in immunomodulation
WO2018018082A1 (en)	2016-07-26	2018-02-01	The Australian National University	Immunostimulatory compositions and uses therefor
US12416015B2 (en)	2017-09-15	2025-09-16	The Board Of Trustees Of The Leland Stanford Junior University	Multiplex production and barcoding of genetically engineered cells
US10917454B1 (en)	2019-08-01	2021-02-09	Rohde & Schwarz Gmbh & Co. Kg	System and method for ATC voice quality assurance
EP4419684A1 (en)	2021-10-21	2024-08-28	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Retroelement-generated transcription factor decoys
WO2023077147A2 (en)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	T-cell vaccines for patients with reduced humoral immunity
CA3237482A1 (en)	2021-11-03	2023-05-11	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Precise genome editing using retrons
WO2023141602A2 (en)	2022-01-21	2023-07-27	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
EP4499839A1 (en)	2022-03-25	2025-02-05	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Methods of assessing engineered retron activity, and uses thereof
WO2023183589A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Rt-dna fidelity and retron genome editing
WO2023183627A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2024020346A2 (en)	2022-07-18	2024-01-25	Renagade Therapeutics Management Inc.	Gene editing components, systems, and methods of use
WO2024044673A1 (en)	2022-08-24	2024-02-29	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en)	2022-08-25	2024-02-29	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
WO2024233791A1 (en)	2023-05-11	2024-11-14	Seelos Therapeutics, Inc.	Methods of treating neurodegenerative disorders
WO2025081042A1 (en)	2023-10-12	2025-04-17	Renagade Therapeutics Management Inc.	Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en)	2024-01-17	2025-07-24	Renagade Therapeutics Management Inc.	Improved gene editing system, guides, and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0110385A2 (en) *	1982-11-30	1984-06-13	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Process for producing poxvirus recombinants for expression of foreign genes
WO1986000528A1 (en) *	1984-07-05	1986-01-30	Genex Corporation	Cloned gene and method for making and using the same
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
WO1986005806A1 (en) *	1985-03-29	1986-10-09	National Research Development Corporation	Infectious bronchitis virus spike protein
WO1988002022A1 (en) *	1986-09-22	1988-03-24	Commonwealth Scientific And Industrial Research Or	Recombinant poxviruses
EP0261940A2 (en) *	1986-09-23	1988-03-30	Applied Biotechnology, Inc.	Pseudorabies vaccines and DNA vectors for recombination with pox viruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
FR2563434B1 (fr) *	1984-04-25	1986-07-25	Transgene Sa	Vaccin contre la rage et procede pour sa preparation
DD235669A1 (de) *	1985-03-26	1986-05-14	Akad Wissenschaften Ddr	Verfahren zur herstellung eines blv-kodierten huellproteins
AU6170486A (en) *	1985-08-23	1987-02-26	Advanced Genetics Research Institute	Defective viral vaccines
AU607399B2 (en) *	1985-09-09	1991-03-07	Cetus Corporation	Infectious recombinant virus vaccine for feline leukemia
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU602875B2 (en) *	1985-12-18	1990-11-01	British Technology Group Limited	Newcastle disease virus gene clones
AU8075787A (en) *	1986-09-22	1988-04-07	Australian National University, The	Recombinant poxviruses
EP0284416B1 (en) *	1987-03-27	1995-02-22	Nippon Zeon Co., Ltd.	Recombinant avipoxyvirus
DE10399031I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
GB8724885D0 (en) *	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
FR2632863B2 (fr) *	1987-10-29	1990-08-31	Transgene Sa	Virus du fowlpox recombinant et vaccins derives de ces virus
DE68912441T2 (de) *	1988-06-24	1994-05-11	British Tech Group	Nichtessentielle Geflügelpockenvirus-Regionen.
AU625584B2 (en) *	1989-03-08	1992-07-16	Health Research Inc.	Recombinant poxvirus host selection system
KR100372934B1 (ko) *	1990-09-25	2003-12-24	캔탑 파마슈티칼스 리서취 리미티드	형질 상보성 세포주에 의해 생성된 바이러스 결손 백신

1987
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
1988
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active Expired - Lifetime
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en not_active Ceased
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
EP0110385A2 (en) *	1982-11-30	1984-06-13	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Process for producing poxvirus recombinants for expression of foreign genes
WO1986000528A1 (en) *	1984-07-05	1986-01-30	Genex Corporation	Cloned gene and method for making and using the same
WO1986005806A1 (en) *	1985-03-29	1986-10-09	National Research Development Corporation	Infectious bronchitis virus spike protein
WO1988002022A1 (en) *	1986-09-22	1988-03-24	Commonwealth Scientific And Industrial Research Or	Recombinant poxviruses
EP0261940A2 (en) *	1986-09-23	1988-03-30	Applied Biotechnology, Inc.	Pseudorabies vaccines and DNA vectors for recombination with pox viruses

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AVIAN DISEASES, VOL. 30, NO. 1, 1985; S. 24-27 *
BIOESSAYS, VOL. 5, 1986; S. 249-251 *
BIOTECHNOLOGY: POTENTIALS AND LIMITATIONS, DAHLENS KONFERENZEN 1986; S. 155 U. 161-162 *
JOURNAL OF GENERAL VIROLOGY, VOL. 67, 1986; S. 1591-1600 *
JOURNAL OF GENERAL VIROLOGY, VOL. 67, 1986; S. 6563 *
JOURNAL OF VIROLOGY, VOL. 62, 1988; S. 367 *
NATURE, VOL. 317, 1985; S. 813-815 *
VIROLOGY, VOL. 156, 1987; S. 335 *
VIROLOGY, VOL. 160, 1987; S. 203 *
VIRUS GENES, VOL. 1, 1987; S. 7-21 *
VIRUS RESEARCH, VOL. 10, 1988; S. 343 *
VIRUS RESEARCH, VOL. 10, 1988; S. 65 *
ZBL. BAKT. HYG., I. ABT. ORIG. B 167, 1978; S. 375-390 *

Also Published As

Publication number	Publication date
DE3890874C5 (de)	2005-10-20
DE10399031I1 (de)	2004-01-29
NL300138I1 (nl)	2004-02-02
GB8908921D0 (en)	1989-08-02
NL195051C (nl)	2003-07-01
NL8820679A (nl)	1989-07-03
ATA900788A (de)	1995-05-15
GB2217718B (en)	1992-05-20
AR241939A1 (es)	1993-01-29
AU690210B2 (en)	1998-04-23
NL300138I2 (nl)	2004-03-01
FR2621487B1 (fr)	1991-10-18
DK175904B1 (da)	2005-06-06
AU2427588A (en)	1989-05-02
NZ225970A (en)	1991-01-29
CH679934A5 (da)	1992-05-15
DK203689D0 (da)	1989-04-27
JP3826055B2 (ja)	2006-09-27
DE10399032I1 (de)	2004-01-29
JP2002186494A (ja)	2002-07-02
IL87581A0 (en)	1989-01-31
JP3348156B2 (ja)	2002-11-20
LU90951I2 (fr)	2003-01-15
WO1989003429A1 (en)	1989-04-20
KR890701757A (ko)	1989-12-21
KR970011149B1 (ko)	1997-07-07
LU91039I2 (fr)	2003-11-05
GB2217718A (en)	1989-11-01
DE3890874C2 (de)	2003-03-13
DK203689A (da)	1989-06-27
IT1229484B (it)	1991-09-03
IT8821772A0 (it)	1988-08-29
FR2621487A1 (fr)	1989-04-14
NL300130I2 (nl)	2005-11-01
JPH02500879A (ja)	1990-03-29
JP2002348255A (ja)	2002-12-04
BE1002134A5 (fr)	1990-07-24
NL300130I1 (nl)	2003-09-01
NL300139I1 (nl)	2004-02-02
AU1628895A (en)	1995-08-17
CH679933A5 (da)	1992-05-15
DE10299049I1 (de)	2004-07-01

Publication	Publication Date	Title
AT408549B (de)	2001-12-27	Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes
US5174993A (en)	1992-12-29	Recombinant avipox virus and immunological use thereof
US5505941A (en)	1996-04-09	Recombinant avipox virus and method to induce an immune response
DE4090565C2 (de)	2000-03-09	Rekombinantes Herpesvirus-Pockenvirus-Vakzin
AT400955B (de)	1996-05-28	Rekombinantes pockenvirus-wirtsselektionssystem
DE69535359T2 (de)	2007-10-11	Rekombinantes herpesvirus aus trufhähnen und seine verwendungen
DE69532068T2 (de)	2004-08-26	Rekombinanter lebender Vogel-Impfstoff, der ein Truthahn-Herpesvirus Vektor gebraucht
DE60314823T3 (de)	2017-11-16	Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DE68912441T2 (de)	1994-05-11	Nichtessentielle Geflügelpockenvirus-Regionen.
DE69533305T2 (de)	2005-09-01	Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
DE68920610T2 (de)	1995-08-31	Rekombinantes Virus der Marekschen Krankheit und Vakzin.
DE69735594T2 (de)	2006-11-23	Rekombinanter schweinepockenvirus
DE4192786B4 (de)	2006-08-24	Masernvirus-Rekombinanter Pockenvirus-Impfstoff
DE69627526T2 (de)	2004-04-01	Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
DE69435081T2 (de)	2008-06-12	Rekombinanter adenovirusvektor für geflügel
DE3752182T2 (de)	1998-08-06	Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten
DE69627109T2 (de)	2003-12-18	REKOMBINANTES HERPESVIRUS UNTER DER VERWENDUNG DES gB GENPROMOTERS
Smith et al.	1994	Development and trial of a bovine herpesvirus 1‐thymidine kinase deletion virus as a vaccine
WO2007115385A2 (en)	2007-10-18	Transfer plasmidic vector and recombinant canarypox virus
CA2084064A1 (en)	1992-01-03	Recombinant pigeon pox virus vaccine
CA1341403C (en)	2002-11-26	Recombinant a vipox virus
AU761321B2 (en)	2003-06-05	Recombinant viruses, vaccines containing them and in vitro cell cultures thereof
DK175980B1 (da)	2005-10-24	Recombinante vacciniavira og anvendelsen af samme
AU725985B2 (en)	2000-10-26	Recombinant virus
DD297997A5 (de)	1992-01-30	Proteine, vakzine und nukleinsaeuren

Legal Events

Date	Code	Title	Description
2002-11-15	SZA	Application filed for a certificate of protection	Free format text: SZ 31/2002, 20020906
2003-10-15	SZA	Application filed for a certificate of protection	Free format text: ERZEUGNIS: INFLUENZA A/EQUI-2/KENTUCKY/94-REKOMBINANTE DES KANARIENPOCKENVIRUS IN KOMBINATION MIT INFLUENZA A/EQUI-2/NEWMARKET/2/93-REKOMBINATE DES KANARIENPOCKENVIRUS UND MIT CLOSTRIDIUM TETANI-TOXOID Spc suppl protection certif: SZ 26/2003 Filing date: 20030904 Free format text: ERZEUGNIS: INFLUENZA A/EQUI-2/KENTUCKY/94-REKOMBINANTE DES KANARIENPOCKENVIRUS IN KOMBINATION MIT INFLUENZA A/EQUI-2/NEWMARKET/2/93-REKOMBINATE DES KANARIENPOCKENVIRUS Spc suppl protection certif: SZ 27/2003 Filing date: 20030904
2008-10-15	EZF	Grant of a certificate of protection	Free format text: SZ 27/2003, 20030904, EXPIRES:20130824 Spc suppl protection certif: SZ 27/2003 Filing date: 20030904 Expiry date: 20130824 Free format text: SZ 31/2002, 20020906, EXPIRES:20130824 Spc suppl protection certif: SZ 31/2002 Filing date: 20020906 Expiry date: 20130824 Free format text: SZ 26/2003, 20030904, EXPIRES:20130824 Spc suppl protection certif: SZ 26/2003 Filing date: 20030904 Expiry date: 20130824
2009-05-15	ELA	Expired due to lapse of time
2014-03-15	SPCX	Expiry of an spc	Free format text: PRODUCT NAME: INFLUENZA A/EQUI-2/KENTUCKY/94 (H3N8) - REKOMBINANTE DES KANARIENPOCKENVIRUS UND INFLUENZA A/EQUI-2/NEWMARKET/2/93 (H3N8) -REKOMBINANTE DES KANARIENPOCKENVIRUS; REGISTRATION NO/DATE: EU/2/03/038/001-004 20030306 Spc suppl protection certif: 26/2003 Filing date: 20030904 Expiry date: 20080824 Extension date: 20130824 Effective date: 20130824 Free format text: PRODUCT NAME: INFLUENZA A/EQUI-2/KENTUCKY/94 (H3N8) -REKOMBINANTE DES KANARIENPOCKENVIRUS UND INFLUENZA A/EQUI-2/NEWMARKET/2/93 (H3N8) - REKOMBINANTE DES KANARIENPOCKENVIRUS; REGISTRATION NO/DATE: EU/2/03/037/001-004 20030306 Spc suppl protection certif: 27/2003 Filing date: 20030904 Expiry date: 20080824 Extension date: 20130824 Effective date: 20130824 Free format text: PRODUCT NAME: ENV- UND GAG-FELV UMFASSENDE REKOMBINANTEN DES KANARIENPOCKENVIRUS; NAT. REGISTRATIONNO/DATE: EU/2/02/031/001 UND EU/2/02/031/002 20020308; FIRST REGISTRATION: EU EU/2/02/031/001 UND 20020308 Spc suppl protection certif: 31/2002 Filing date: 20020906 Expiry date: 20080824 Extension date: 20130824 Effective date: 20130824